Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff

Bristol-Myers Squibb (BMY) looks undervalued at 8.9x forward P/E; see growth catalysts, FDA/Phase 3 timelines, and a $68 ...